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Background
Ultra-deep Pyrosequencing (UDPS) offers the opportu-
nity to analyze the co-receptor usage of each variant
present in a viral quasispecies. Aim of the study was to
assess co-receptor usage by UDPS, in comparison with a
reference phenotypic test, in patients candidates to
CCR5 antagonists treatment, in both circulating and
proviral HIV-1.
Methods
Seventeen patients were enrolled. Trofile phenotypic test
was performed by standard in 9 and by enhanced proce-
dures in 8 patients. UDPS was carried out on both
plasma virus RNA and on PBMC proviral DNA, ampli-
fying env V3 loop region. Genotypic prediction of co-
receptor usage was obtained by Position Specific Score
Matrix analysis. Comparison between phenotypic and
genotypic assays was performed considering a threshold
of 5% and 0.3% for X4 detection (standard and
enhanced Trofile sensitivity).
Results
After editing, a total of 130,999 V3 sequences were consid-
ered, with a mean coverage per site of 5,955. Concordance
between phenotypic and UDPS results was 0.60 ± 0.24
(Cohen K index ± SE). Discordant results were observed
in one case with standard and in 2 cases with enhanced
trofile test. Only one patient, eligible to CCR5 antagonist
treatment based on Trofile results, showed X4 variants in
the circulation by UDPS at a frequency higher than that of
Trofile sensitivity. Quasispecies archived in PBMC tended
to be more heterogeneous than that found in circulating
virus. All patients, with only one exception, harboured in
proviral DNA X4 variants at variable frequency (from
0.07% to 53%).
Discussion
UDPS allows a detailed characterization of HIV V3 qua-
sispecies in both circulating and archived sequences.
Almost concordant results were obtained by UDPS and
Trofile for prediction of co-receptor usage of plasma vir-
ions. In proviral DNA, X4 variants were commonly
observed at variable frequencies. The importance of
archived X4 variants in influencing clinical response to
CCR5 antagonists is a crucial point to be addressed.
Published: 11 May 2010
doi:10.1186/1742-4690-7-S1-O11
Cite this article as: Abbate et al.: Co-receptor usage prediction at
quasispecies level using ultra-deep pyrosequencing on both circulating
and proviral hiv in patients candidates to CCR5 antagonist treatment.
Retrovirology 2010 7(Suppl 1):O11.
* Correspondence: abbate@inmi.it
INMI L.Spallanzani, Rome, Italy
Abbate et al. Retrovirology 2010, 7(Suppl 1):O11
http://www.retrovirology.com/content/7/S1/O11
© 2010 Abbate et al; licensee BioMed Central Ltd.